At the IQ Innovation Award Central Germany 2021, our project for the development of novel Cell Therapeutics for the treatment of cartilage defects was awarded twice. Out of 140 applications and 30 finalists, BioPlanta was ranked second place overall and second place in the Life Science cluster. We are particularly proud of these placements, as top-class juries have twice recognised our development of a stem cell drug.
Where you can meet us:
The shareholder of BioPlanta GmbH already founded a company of the same name in 1992, which was extraordinarily successful in the field of phytoremediation and development of phytotherapeutics and was merged in 2012 with Europe's second largest listed stem cell bank.
In 2017, Animal Service UG was transformed into BioPlanta GmbH, which is very active in the field of biotechnology/life sciences, particularly in the development of applications for regenerative medicine. As a research-based pharmaceutical company, BioPlanta is engaged in the production and development of biomedical drugs for clinical application in humans, in particular for the treatment of orthopaedic diseases. The focus is on both allogeneic and autologous therapy concepts. The main focus of the company is in the area of contract development and manufacturing of stem cell-based cell preparations.
Research & development at BioPlanta GmbH aims to increase product quality by extending quality assurance measures as well as to expand the application possibilities of stem cell-based products for new indications.
In addition, BioPlanta advises German and international clients on the establishment and strategic development of biotechnology companies, in particular in the field of regenerative medicine.
Cell therapy is currently undergoing a paradigm shift from autologous to allogenic therapy concepts.
|Painful, invasive collection||No collection morbidity|
|Higher patient costs
(Removal costs cartilage approx. 2.250 EUR)
|Lower patient costs|
|Lower margins (10%)||Higher margins (40%)|
|4 - 6 weeks for manufacture||Immediately available|
|No rejection reaction||Very low probability of rejection when using young MSC|
|Limited bulk production||24/7 bulk production possible|
|High number of collection centres||Few collection centres sufficient|
|1 product/patient||1 product for multiple patients|